Humanitas Istituto Clinico Catanese S.p.A. — Clinical Trial Site

42 Registered trials

25 Currently recruiting

Organisation

Humanitas Istituto Clinico Catanese S.p.A.

Location

Misterbianco, Italy

Identifier

ORG-100041356

Address

Strada Provinciale 54 Contrada Cubba 11, 95045, Italy

Departments

#4111;Oncologia Medica
039033: Oncologia Medica
4103: NA
Dipartimento di Oncologia
Humanitas Istituto Clinico Catanese
Medical Oncology
Medical Oncology and Hematology Unit
Medical Oncology Department
Medical Oncology Unit
Oncologia
Oncologia Humanitas Istituto Clinico Catanese S.p.A.
Oncologia e Ematologia
Oncologia ed Ematologia Medica
Oncologia Medica
Oncologia Medica ed Ematologia
Oncologia Medica Universitaria
Oncology
Radioterapia
U.O. Chirurgia Oncologica
U.O. Oncologia Medica
U.O. Oncologia Medica ed Ematologia
U.O. Oncologia Medica Universitaria
U.O. Oncologica Medica
Unità Operativa di Oncologia Medica e Oncoematologia
UO Oncologia Medica
UOC Oncologia Medica

Clinical trials at this site (42)

Search interface

Clinical trial of MK-2870 in combination with pembrolizumab in people who have had surgery to treat triple negative breast cancer Recruiting

2023-504962-52-00 Triple negative breast cancer. 5 2024-07-10
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting

2023-504031-41-00 ER+/HER2- Early Breast Cancer 5 2024-03-25
Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib… Recruiting

2023-503708-10-00 Locally advanced or metastatic breast cancer 5 2024-02-20
"APalutamide and stEReotactic body radiation therapy for low burden metastatic hormone senSItive prostate cancer, a rANdomized trial -PERSIA… Recruiting

2022-501894-37-00 prostate cancer 4 2023-03-02
NEOadjuvant Abemaciclib and GIredestrant triaL in patients with ER-positive, HER2-negative Early breast cancer Ended

2023-510153-42-00 ER-positive, HER2-negative Early breast cancer 4 2024-11-25
A study to Evaluate Efficacy and Safety of Giredestrant Compared with Fulvestrant (plus a CDK4/6 inhibitor), in Participants with ER+ HER2-N… Ended

2022-502980-39-00 Estrogen receptor (ER)-positive, HER2-negative advanced 5 2024-01-25
TACTIVE-U: An Umbrella Study to Investigate the Safety and Antitumor Activity of ARV-471 in Combination With Other Medicines in Adults With … Ended

2022-502231-19-00 ER+/HER2- Advanced or Metastatic Breast Cancer 9 2024-01-02
Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With HR+/HER2− Metastatic Breast Cancer Who Have Received … Ended

2022-502593-17-00 Locally advanced or metastatic hormone receptor (HR)-po 5 2023-09-19
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended

2022-501024-20-00 ER+/HER2- Early Breast Cancer 5 2023-07-25
A clinical trial to compare the effectiveness and safety of giredestrant with a subcutaneous combination of pertuzumab and trastuzumab versu… Ended

2022-500014-26-00 Locally-Advanced unresectable or Metastatic breast canc 5 2022-06-24
Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer Ended

2023-506771-10-00 Breast Neoplasm, Neoplasm Metastasis 5 2022-03-11
A study of tucatinib versus placebo in combination with pertuzumab and trastuzumab for subjects with advanced or metastatic HER2+ breast can… Ended

2023-503826-37-00 Unresectable locally-advanced or metastatic HER2+ breas 5 2022-02-11
A randomized, double-blind, Phase III Study of AZD9833 plus CDK4/6 inhibitor in patients with metastatic breast cancer with detectable ESR1 … Ended

2023-503990-39-00 Estrogen Receptor-Positive, HER-2 negative Advanced Bre 5 2021-09-30
Phase Ib/III Study of Capivasertib + CDK4/6 Inhibitors + Fulvestrant as Treatment for Advanced/Metastatic HR+/HER2-Breast Cancer (CAPItello-… Ended

2023-504997-39-00 Hormone Receptor-Positive and Human Epidermal Growth Fa 5 2021-06-14
A study to investigate the efficacy and safety of trastuzumab deruxtecan in patients With or Without Brain Metastasis Who Have Previously-Tr… Ended

2024-510588-53-00 Treatment of patients with HER2-positive breast cancer 11 2021-06-10
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Pa… Ended

2023-506911-16-00 ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVAN 5 2020-12-04
A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant trea… Ended

2023-510357-42-00 hormone receptor (HR)-positive, HER2-negative, early br 5 2019-05-22
A Phase 1/2 Study of DCC-3116 in Patients With MAPK Pathway Mutant Solid Tumors Ended

2022-501474-19-00 Non-Small Cell Lung Cancer 7